1Ereshefsky L.Drug-drug interactions involving antidepressants:focus on venlafaxine[J].Journal of clinical Psychopharmacology,1996,16(Suppl2):37-50.
2Facciola G,Scordo MG,Spina E.No effect of the new antidepressant reboxetine on CYP2D6activity in healthy volunteers[J].Ther Drug Monit,1999,21(5):577-279.
3Reis M,Lundmark J,Bjrk H,et al.Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clini-cal setting[J].Ther Drug Monit,2002,24(4):545-553.
4Spina E,Scordo MG,D’Arrigo C.Metabolic drug interaction with new psychotropic agent[J].Fund&Clin Pharmacol,2003,17:517-538.
5Nivoix Y,Ubeaud-Sequier G,Engel P,et al.Drug drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care[J].Current Drug Metabolism,2009,10:395-409.
6Paris BL,Ogilvie BW,Scheinkoenig JA,et al.In vitro inhibition and induction of human liver cytochrome p450enzymes by milnaci-pran[J].Drug Metab Dispos,2009,37(10):2045-2054.
7Fric M,Pfuhlmann B,Laux G,et al.The influence of smoking onthe serum level of duloxetine[J].Pharmacopsychiatry.2008,41(4):151-155.
8Preskorn SH,Greenblatt DJ,Flockhart D.et al.Comparison of duloxetine,escitalopram,and sertraline effects on cytochrome P450.
9D6function in healthy volunteers[J].J Clin Psychopharmacol,2007,27(1):28-34.
10Heeringa M,Beurskens R,Schouten W,et al.Elevated plasma levels of clozapine after concomitant use of fluvoxamine[J].Pharm World Sci.1999,21(5):243-244.
